Growth & profitability
- Revenue has grown 41.4% per year over the past 5 years.
- Operating margin has expanded, at 37.1% in the latest year.
Financial health
- Operating income covered interest expense 24× in the latest year.
AUPH Financials Aurinia Pharmaceuticals Inc.
8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $283M | $287M | 88.5% | 37.1% | — | — | $80M |
| 2024 | $235M | $6M | 88.0% | -2.0% | — | — | $83M |
| 2023 | $176M | -$78M | 91.9% | -52.2% | — | — | $49M |
| 2022 | $134M | -$108M | 95.8% | -83.2% | — | — | $94M |
| 2021 | $46M | -$181M | 97.6% | -396.3% | — | — | $232M |
| 2020 | $50M | -$103M | 100.0% | -208.1% | — | — | $272M |
| 2019 | $318000 | -$88M | 100.0% | -28598.4% | — | — | $306M |
| 2018 | $463000 | -$53M | 0.0% | -11930.9% | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $78M | $34M | 91.6% | 53.3% | — | — | $41M |
| Dec '25 | $77M | $211M | 88.6% | 43.1% | — | — | $80M |
| Sep '25 | $73M | $32M | 88.9% | 40.5% | — | — | $73M |
| Jun '25 | $70M | $22M | 89.8% | 28.7% | — | — | $53M |
| Mar '25 | $62M | $23M | 86.3% | 35.0% | — | — | $66M |
| Dec '24 | $60M | $1M | 90.7% | -2.8% | — | — | $83M |
| Sep '24 | $68M | $14M | 91.1% | 17.3% | — | — | $37M |
| Jun '24 | $57M | $722000 | 84.4% | -2.6% | — | — | $33M |
| Mar '24 | $50M | -$11M | 84.6% | -26.3% | — | — | $64M |
| Dec '23 | $45M | -$27M | 88.0% | -65.8% | — | — | $49M |
| Sep '23 | $55M | -$13M | 87.6% | -29.8% | — | — | $46M |
| Jun '23 | $41M | -$11M | 96.2% | -39.0% | — | — | $81M |
| Mar '23 | $34M | -$26M | 98.8% | -86.0% | — | — | $88M |
| Dec '22 | $28M | -$26M | 95.2% | -98.8% | — | — | $94M |
| Sep '22 | $56M | -$9M | 95.6% | -17.0% | — | — | $85M |
| Jun '22 | $28M | -$36M | 94.3% | -127.7% | — | — | $151M |
| Mar '22 | $22M | -$38M | 98.8% | -175.2% | — | — | $132M |
| Dec '21 | $23M | -$33M | 97.9% | -139.7% | — | — | $232M |
| Sep '21 | $15M | -$50M | 98.3% | -343.3% | — | — | $58M |
| Jun '21 | $7M | -$47M | 95.3% | -712.0% | — | — | $122M |
Valuation over time
How the market has priced AUPH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 215.0× (Dec '24) to 8.5× (Jun '26).
- The price-to-sales ratio has fallen from 11.3× (Mar '23) to 8.6× (Jun '26).
P/E
P/S
Frequently asked questions
Is AUPH growing its revenue and profit?
Over the past 5 years, Aurinia Pharmaceuticals Inc.'s revenue has grown 41.4% per year. These are computed facts, not advice.
How much debt does AUPH have?
As of FY2025, Aurinia Pharmaceuticals Inc. reported — of total debt against $80M of cash; operating income covered interest expense 24×.
What is AUPH's profit margin?
In FY2025, gross margin was 88.5%, operating margin 37.1%, and net margin 101.5%.
What is AUPH's P/E ratio?
As of Jun '26, Aurinia Pharmaceuticals Inc. traded at a price-to-earnings ratio of about 8.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.